12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Company News  |  Deals

Amgen, Hypermarcas deal

Hypermarcas will return Brazilian rights to Amgen for colorectal cancer drug Vectibix panitumumab and for hyperparathyroidism and hypercalcemia drug Mimpara cinacalcet, which are...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >